Search

Your search keyword '"Fabris, L."' showing total 79 results

Search Constraints

Start Over You searched for: Author "Fabris, L." Remove constraint Author: "Fabris, L." Topic med/12 - gastroenterologia Remove constraint Topic: med/12 - gastroenterologia
79 results on '"Fabris, L."'

Search Results

1. Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine

2. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis

3. Oxidative Stress in Non-Autoimmune Liver Diseases

4. Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study

5. The multitasking behavior of cholangiocyte in the reaction to liver damage

6. Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study

7. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants

8. Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis

9. Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study)

10. Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study

11. Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study)

12. Protein kinase a-dependent pSer(675) -β-catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis

13. Β-CATENIN-MEDIATED CXCL1 AND CXCL10 SECRETION BY FIBROCYSTIN-DEFECTIVE CHOLANGIOCYTES REGULATES PERIBILIARY RECRUITMENT OF FIBROCYTES IN CONGENITAL HEPATIC FIBROSIS

14. Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.)

15. Pathway-based analysis of primary biliary cirrhosis genome-wide association studies

16. Health Related Quality of Life in the Major Liver Conditions

17. CXCL1 and CXCL10 secretion by fibrocistidefective cholangiocytes recruits peribiliary fibrocytes in congenital hepatic fibrosis

18. SELECTIVE REDUCTION IN S100A4 NUCLEAR EXPRESSION BY LOW-DOSE PACLITAXEL HALTS INVASIVENESS OF HUMAN CHOLANGIOCARCINOMA CELLS THROUGH A RAC1-INDEPENDENT, RHO-A/CDC42-DEPENDENT MECHANISM

19. SELECTIVE REDUCTION IN S100A4 NUCLEAR EXPRESSION BY LOW-DOSE PACLITAXEL HALTS INVASIVENESS OF HUMAN CHOLANGIOCARCINOMA CELLS THROUGH A RAC1-INDEPENDENT, RHO-A/CDC42-DEPENDENT MECHANISM

20. MONOCYTE/MACROPHAGE PERIBILIARY RECRUITMENT BY PKHD1-DEFECTIVE CHOLANGIOCYTES INDUCES EXPRESSION OF aVb6 INTEGRIN ON BILIARY CYSTS VIA TGF-Β1 AND TNF-Α IN CONGENITAL HEPATIC FIBROSIS

21. Role of angiogenesis and angiogenic factors for cholangiocyte growth

22. Reaction of cholangiocytes to inflammatory injury

23. The monoethylglycinexylidide test for grading of liver cirrhosis

24. Pathophysiology of the biliary epithelium

25. Malassorbimento

26. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis

27. Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase-A/5-Hydroxytryptamine/5-Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis

28. Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine

29. The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma

30. Macrophage recruitment by fibrocystin‐defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis

31. Molecular mechanisms driving cholangiocarcinoma invasiveness: an overview

32. Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness

33. The healthy biliary tree: Cellular and immune biology

34. Neural cell adhesion molecule and polysialic acid in ductular reaction: The puzzle is far from completed, but the picture is becoming more clear

35. Low dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma

36. Revisiting Epithelial-to-Mesenchymal Transition in Liver Fibrosis: Clues for a Better Understanding of the 'Reactive' Biliary Epithelial Phenotype

37. Development of the bile ducts: Essentials for the clinical hepatologist

38. Epithelial-Mesenchymal Interactions in Biliary Diseases

39. Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation

40. Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma?

41. Pathophysiology of Cholangiopathies

42. Isolated idiopathic bile ductular hyperplasia in patients with persistently abnormal liver function tests

43. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes

44. Osteopontin: a new player in regulating hepatic ductular reaction and hepatic progenitor cell responses during chronic liver injury

45. Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study)

46. Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study)

47. Na+-dependent and -independent Cl?/HCO3? exchange mediate cellular HCO3? transport in cultured human intrahepatic bile duct cells

48. Notch signaling regulates tubular morphogenesis during repair from biliary damage in mice

49. Notch signalling beyond liver development: emerging concepts in liver repair and oncogenesis

Catalog

Books, media, physical & digital resources